Within China's vitamin, specialty API, and pharmaceutical formulation industries, the Brother Group has established two key business pillars: Brother Enterprises Holding Co., Ltd., the group's strategic holding platform, and Zhejiang Brothers Pharmaceutical Co., Ltd., its dedicated pharmaceutical formulation company. Together, they form the backbone of Brother's integrated healthcare strategy, connecting upstream raw material manufacturing with downstream finished pharmaceutical products.
Founded in 1991 in Haining, Zhejiang Province, Brother Enterprises Holding Co., Ltd. serves as the parent company of the Brother Group. Listed on the Shenzhen Stock Exchange in 2011 (Stock Code: 002562), the company oversees the group's worldwide operations, including manufacturing, research and development, investment, and international business expansion.
Brother Enterprises Holding manages six major business divisions covering vitamins, pharmaceutical ingredients, flavors and fragrances, leather chemicals, catalysts, and chromium chemicals.
The group operates large-scale manufacturing bases in Zhejiang, Jiangsu, Jiangxi, and South Africa. Subsidiaries including Jiangsu Brother Vitamins Co., Ltd., Jiangxi Brother Pharmaceutical Co., Ltd., and Zhejiang Brothers Pharmaceutical Co., Ltd. are all wholly owned by the parent company.
Rather than participating directly in manufacturing, the holding company is responsible for corporate strategy, capital investment, global supply chain management, regulatory compliance, international market development, and long-term capacity planning, serving as the decision-making center for the entire organization.
Supported by its production facilities in Zhejiang and Jiangsu, the group has established large-scale manufacturing capabilities for Vitamin B1, Vitamin B3, Vitamin K3, iodinated contrast media intermediates, vanillin, and other specialty chemical products.
These products serve customers across the feed, food, pharmaceutical, and fine chemical industries throughout Europe, North America, Southeast Asia, the Middle East, and many other international markets.
Because many key raw materials are produced internally, downstream pharmaceutical subsidiaries benefit from reliable supply, competitive costs, and enhanced manufacturing efficiency through vertical integration.
Brother Enterprises Holding has established a three-level innovation system consisting of a corporate research institute, technology centers at each manufacturing base, and specialized business-unit R&D teams.
Working closely with leading universities and research institutes, the group focuses on green synthesis technologies, pharmaceutical purification, process optimization, and formulation development. Research成果 are shared across the organization, providing Zhejiang Brothers Pharmaceutical with both advanced technologies and high-quality intermediates for pharmaceutical product development.
Established in 2018 and located in Qiantang, Zhejiang Province, Zhejiang Brothers Pharmaceutical Co., Ltd. is a wholly owned subsidiary dedicated to pharmaceutical formulations.
Its creation marked an important milestone in the Brother Group's development by extending its business beyond APIs and chemical intermediates into finished pharmaceutical products, completing the final stage of the pharmaceutical value chain.
While the Jiangsu and Jiangxi manufacturing bases specialize in vitamins, intermediates, and APIs, Zhejiang Brothers Pharmaceutical focuses on pharmaceutical formulation development, product registration, manufacturing, and commercialization.
Leveraging the group's internally produced vitamins and specialty APIs, the company develops oral nutritional products, dietary supplements, and specialty pharmaceutical formulations covering neurological health, metabolic support, and nutritional supplementation.
This integrated model allows Brother to combine in-house API manufacturing with proprietary finished dosage forms, creating a complete pharmaceutical ecosystem.
The company is developing multiple pharmaceutical dosage forms, including tablets, capsules, and oral liquid formulations.
With more than twenty products currently under development, several have already entered China's regulatory registration process, while additional formulation products are being prepared for international registration through the group's global marketing network.
The company has also established several biotechnology research subsidiaries dedicated to innovative generic pharmaceuticals, nutritional healthcare products, and future pharmaceutical innovation projects.
The integration between Brother Enterprises Holding and Zhejiang Brothers Pharmaceutical creates significant operational advantages.
Upstream, Jiangsu Brother Vitamins and Jiangxi Brother Pharmaceutical provide a stable supply of high-purity Vitamin B1, Vitamin B3, Vitamin K3, iodinated contrast media APIs, and other specialty ingredients, eliminating dependence on external suppliers and improving production cost control.
Throughout manufacturing, the company benefits from the group's unified quality assurance, environmental protection, and safety management systems while complying with international standards including ISO, FCC, USP, and REACH requirements where applicable.
Downstream, finished pharmaceutical products can utilize the group's established domestic and international sales network, reducing market entry costs and accelerating commercialization.
Many chemical manufacturers remain focused solely on raw materials and struggle to enter higher-value pharmaceutical formulation markets.
Brother has addressed this challenge through a business structure that combines centralized strategic management with specialized pharmaceutical development.
Brother Enterprises Holding oversees capital investment, manufacturing resources, raw material production, and global market development, building a competitive foundation through large-scale integrated manufacturing.
Zhejiang Brothers Pharmaceutical concentrates on formulation research, pharmaceutical registration, product development, and commercial sales, allowing the group to expand into higher-margin pharmaceutical markets.
Together, these complementary roles create a balanced and sustainable business model.
When raw material prices fluctuate, internal manufacturing helps stabilize production costs for pharmaceutical formulations.
At the same time, higher-value finished pharmaceutical products provide stronger profitability, helping offset cyclical fluctuations in commodity vitamin markets and improving the group's long-term financial stability.
Both the corporate headquarters in Haining and the pharmaceutical formulation base in Qiantang are located within Zhejiang Province, enabling efficient collaboration in talent development, research, logistics, and regulatory coordination.
Supported by Zhejiang's strong life sciences ecosystem and favorable industrial policies, the group continues to increase investment in pharmaceutical innovation while strengthening its integrated vitamin and pharmaceutical manufacturing platform.
Global demand continues to expand for animal nutrition, dietary supplements, and specialty pharmaceuticals. As profit margins for commodity raw materials become increasingly competitive, vertical integration from APIs to finished formulations has become an important direction for industry development.
With Brother Enterprises Holding providing strategic leadership, Zhejiang Brothers Pharmaceutical driving pharmaceutical formulation development, and Jiangsu Brother Vitamins together with Jiangxi Brother Pharmaceutical supplying high-quality raw materials and APIs, the Brother Group has established a complete industrial chain covering upstream fine chemicals, pharmaceutical ingredients, and downstream finished dosage forms.
Going forward, the group plans to continue expanding pharmaceutical research and development, enrich its formulation pipeline, and leverage its international business network to introduce more Chinese-made vitamin formulations and specialty pharmaceutical products to global markets.
Brother Enterprises Holding Co., Ltd. represents more than three decades of industrial experience, providing strategic leadership and an integrated manufacturing foundation for the entire group.
Zhejiang Brothers Pharmaceutical Co., Ltd. serves as the group's platform for pharmaceutical innovation, transforming internally produced APIs into high-value finished medicines and healthcare products.
Together, these two companies demonstrate how centralized strategic management combined with specialized pharmaceutical development creates a fully integrated business model. Their close collaboration across raw materials, APIs, and finished formulations continues to strengthen the Brother Group's position as one of China's leading manufacturers in the global vitamin and pharmaceutical industries.
Mobile: +8615371019725
E-mail: sales7@bouling-chem.com
Website: www.brother-pharmaceutical.com
Copyright © Jiangxi Brother Pharmaceutical Co., Ltd. 2026. All right reserved.
